Zacks Investment Research Lowers Oncolytics Biotech (NASDAQ:ONCY) to Hold

Share on StockTwits

Zacks Investment Research downgraded shares of Oncolytics Biotech (NASDAQ:ONCY) from a buy rating to a hold rating in a report issued on Tuesday morning, reports.

According to Zacks, “Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer. “

Separately, ValuEngine lowered Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd.

Shares of NASDAQ:ONCY opened at $1.61 on Tuesday. The company has a quick ratio of 3.39, a current ratio of 3.39 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $32.88 million, a PE ratio of -1.96 and a beta of 2.03. The company has a fifty day moving average of $1.74. Oncolytics Biotech has a fifty-two week low of $1.60 and a fifty-two week high of $5.74.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.21) EPS for the quarter. Equities research analysts forecast that Oncolytics Biotech will post -0.9 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.

See Also: Yield Curve

Get a free copy of the Zacks research report on Oncolytics Biotech (ONCY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with's FREE daily email newsletter.